Spinraza® was FDA approved in December 2016 as the first and only treatment for patient with SMA [7]. It is an antisense oligonucleotide drug that modifies pre-messenger RNA splicing of the SMN2 gene and augments exon 7 inclusion in SMN2, in turn producing a more stable protein that can withstand some degradation [2]. Many studies have been published that show the safety and efficacy of Spinraza® in SMA patients [2, 8-11]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.